ReVision Therapeutics' Series B Round

ReVision Therapeutics raised a round of funding on December 20, 2011. Investors include Avalon Ventures.

ReVision Therapeutics is an ophthalmic biopharmaceutical company developing fenretinide (RT-101) for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in the elde…

Articles about ReVision Therapeutics' Series B Round: